A new hepatoma cell line for toxicity testing at repeated doses

Cell Biology and Toxicology

Volumn 19, Issue 2, 2003, Pages 71-82

  Fabre, Nicolas ^a   Arrivet, E ^a   Trancard, J ^a   Bichet, N ^a   Roome, N O ^a   Prenez, A ^a   Vericat, J A ^a  

^a SANOFI   (France)

Author keywords

Cell line; Differentiation; HBG BC2 cells; HepG2 cells; In vitro toxicity; Repeated treatment

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ACETYLSALICYLIC ACID; PARACETAMOL; PERHEXILINE; PROPRANOLOL;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL LINE; CELL METABOLISM; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; GENE EXPRESSION; HEPATOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; TOXICITY TESTING;

ACETAMINOPHEN; ASPIRIN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LIVER NEOPLASMS; PERHEXILINE; PROPRANOLOL; TOXICITY TESTS;

EID: 0038222335     PISSN: 07422091     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1023304005217     Document Type: Article

References (39)

1. Bondesson I, Ekwall B, Hellberg S, Romert L, Stenberg K, Walum E. MEIC - a new international multicenter project to evaluate the relevance to human toxicity of in vitro cytotoxicity tests. Cell Biol Toxicol. 1989;5:331-47.
2. Buss WC, Jaramillo E, Piatt MK. Coordinate increases and decreases in mitochondrial RNA and ATP syntheses produced by propranolol and rifampicin. Biochem Pharmacol. 1987;36:3293-7.
3. Chen W, Koenigs LL, Thompson SJ, et al. Oxidation of acetaminophen to its toxic quinone imine and non-toxic catechol metabolites by baculovirus-expressed and purified human cytochromes P450 2E1 and 2A6. Chem Res Toxicol. 1998;11:295-301.
4. Cinelli S, Falezza A, Meli C, Ciliutti P, Vericat JA. Alternative methods in toxicology tests: in vitro toxicity. Cytotechnology. 1991;5:51-4.
5. Cooper RG, Evans DA, Price AH. Studies on the metabolism of perhexiline in man. Eur J Clin Pharmacol. 1987;32:569-76.
6. Corcoran GB, Mitchell JR, Vaishnav YN, Horning EC. Evidence that acetaminophen and N-hydroxyacetaminophen form a common arylating intermediate, N-acetyl-p-benzoquinone imine. Mol Pharmacol. 1984;18:536-42.
7. Dai Y, Cederbaum AI. Cytotoxicity of acetaminophen in human cytochrome P450 2E1-transfected HepG2 cells. J Pharmacol Exp Ther. 1995;273:1497-505.
8. Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival. Modification to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods. 1986;89:271-7.
9. Deschamps D, DeBecco V, Fisch C, Fromenty B, Guillouzo A, Pessayre D. Inhibition by perhixiline of oxidative phosphorylation and the beta-oxidation of fatty acids: possible role in pseudoalcoholic liver lesions. Hepatology. 1994;19:948-61.
10. Dierickx P, Ekwall B. Long-term cytotoxicity testing of the first twenty MEIC chemicals by the determination of protein content in human embryonic lung cells. ATLA. 1992;20:285-9.
11. Donato MT, Castell JV, Gómez-Lechón MJ. Prolonged expression of biotransformation activities of rat hepatocytes cocultured with established cell lines. Toxicol In Vitro. 1990;4:461-6.
12. Dong H, Haining RL, Thyummel KE, Retie AE, Nelson SD. Involvement of human cytochrome P450 2D6 in the bioactivation of acetaminophen. Drug Metab Dispos. 2000;28:1397-400.
13. Ekwall B. Screening of toxic compounds in tissue culture. Toxicology. 1980;17:127-42.
14. Ganter P, Jolles G. Methode de Brachet au vert de methylepyronine In: Histochimie normale et pathologique - 2. Paris: Gauthier-Villars; 1970:1521-2.
15. Garle MJ, Fentem JH, Fry JR. In vitro cytotoxicity tests for the prediction of acute toxicity in vivo. Toxicol In Vitro. 1994; 8:1303-12.
16. Glaise D, Ilyin GP, Loyer P, et al. Cell cycle gene regulation in reversibly differentiated new human hepatoma cell lines. Cell Growth Differ. 1998;9:165-76.
17. Goldberg A, Frazier JM. Alternatives to animals in toxicity testing. Sci Am. 1989;261:16-22.
18. Gómez-Lechón MJ, Donato T, Jover R, et al. Expression and induction of a large set of drug-metabolizing enzymes by the highly differentiated human hepatoma cell line BC2. Eur J Biochem. 2001;268:1448-59.
19. Guillouzo A. Liver cell models in in vitro toxicology. Environ Health Perspect. 1998;106:511-27.
20. Hall TJ, James PR, Cambridge G. Development of an in vitro hepatotoxicity assay for assessing the effects of chronic drug exposure. Res Commun Chem Pathol Pharmacol. 1993;79:249-56.
21. Hanley AB, McBridge J, Oehlschlager S, Opraz E. Use of a flow bioreactor as a chronic toxicity model system. Toxicol In Vitro. 1999;13:847-51.
22. Hinson JA, Punford NR, Roberts DW. Mechanisms of acetaminophen toxicity: immunochemical detection of drug-protein adducts. Drug Metab Rev. 1995;27:72-92.
23. LeJossic C, Glaise D, Corcos L, et al. Trans-acting factors, detoxication enzymes and hepatitis B virus replication in a novel set of human hepatoma cell lines. Eur J Biochem. 1996;23:400-9.
24. Martin A, Clynes M. Comparison of 5 microplate colorimetric assays for in vitro cytotoxicity testing and cell proliferation assays. Cytotechnology. 1993;11:49-58.
25. Matthews AM, Roberts DW, Hinson JA, Punford NR. Acetaminophen-induced hepatotoxicity. Analysis of total covalent binding vs. specific binding to cysteine. Drug Metab Dispos. 1996;24:1192-6.
26. Meyeer FP. Indicative therapeutic and toxic drug concentrations in plasma: a tabulation. Int J Clin Pharm Ther. 1994;32:71-81.
27. Mitchell JR, Jollow DJ, Potter WZ, Davis DC, Gillette JR, Brodie BB. Acetaminophen-induced hepatic necrosis, I. Role of drug metabolism. J Pharmacol Exp Ther. 1973;187:185-94.
28. Paillard F, Finot F, Mouche I, Prenez A, Vericat JA. Use of primary cultures of rat hepatocytes to predict toxicity in the early development of new chemical entities. Toxicol In Vitro. 1999:13;693-700.
29. Paliard P, Vitrey D, Fournier G, Belhadjali J, Patricot L, Berger F. Perhexiline maleate-induced hepatitis. Digestion. 1978; 17:419-27.
30. Pessayre D, Mansouri A, Haouzi D, Fromenty B. Hepatotoxicity due to mitochondrial dysfunction. Cell Biol Toxicol. 1999;15:367-73.
31. Pfaller W, Balls W, Clothier R, et al. Novel advanced in vitro methods for long-term toxicity testing. ATLA. 2001;29:393-426.
32. Robbins SL. Pathologic basis of disease, 5th edn. Philadelphia: WB Saunders: 1994:17-21.
33. Scheers EM, Ekwall B, Dierickx PJ. In vitro long term cytotoxicity testing of 27 MEIC chemicals on Hep G2 cells and comparison with acute human toxicity data. Toxicol In Vitro. 2001;15:153-61.
34. Shah RR. Drug-induced hepatotoxicity: pharmacokinetic perspectives and strategies for risk reduction. Adv Drug React Toxicol Rev. 1999;18:181-233.
35. Shoshan-Barmatz V. ATP-dependent interaction of propranolol and local anesthetic with sarcoplasmic reticulum. Biochem J. 1988;256:733-9.
36. Shrivastava R, John GW, Rispat G, Chevalier A, Massingham R. Can the in vivo maximum tolerated concentration be predicted using in vitro techniques? A working hypothesis. ATLA. 1991;19:393-402.
37. Vericat JA, Hanley AB. Chronic toxicity testing in vitro. In: Balls M, van Zeller AM, Halder M, eds. Progress in the reduction, refinement and replacement of animal experimentation. Berlin: Springer Verlag; 2000:1631-8.
38. Wright MC, Paine AJ. Evidence that the loss of rat liver cytochrome P450 in vitro is not solely associated with the use of collagenase, the loss of cell-cell contacts and/or the absence of an extracellular matrix. Biochem Pharmacol. 1992;43:237-43.
39. Zbinden, G. Predictive value of animal studies in toxicology. Regul Toxicol Pharmacol. 1991;14:167-77.